Rituximab as acute rescue therapy for paediatric MOGAD refractory to standard treatment
Abstract
We report the case of a middle childhood boy diagnosed with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), who was resistant to initial steroid pulse therapy and plasma exchange but achieved long-term remission following rituximab (RTX) treatment. Over a 4-year follow-up, the patient experienced no relapse, serum anti-MOG antibodies were undetectable and steroids were successfully tapered and discontinued. This case highlights the potential efficacy of RTX not only as a relapse-preventing agent but also as an acute-phase therapy in paediatric-onset MOGAD.
Fields of Study & Subjects
Multiple Sclerosis Research Studies
Autoimmune Neurological Disorders and Treatments
Peripheral Neuropathies and Disorders
Publication details
- Journal / source
- BMJ Case Reports
- Volume
- 19
- Issue
- 1
- Pages
- e269514–e269514
- Publication date
- 1 January 2026
- Language
- EN